Clinical Trial Update: A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus K Drug in the Treatment of First-line Non-small Cell Lung Cancer(NSCLC) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing TQB2450 plus Anlotinib to a comparator in first-line non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Anlotinib hydrochloride capsules (anlotinib hydrochloride)
• K Drug
• TQB2450

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: UNKNOWN